Reduced quality of life in myasthenia gravis patients: A study on 185 patients from China
暂无分享,去创建一个
[1] B. Fierro,et al. Impact of COVID-19 in AChR Myasthenia Gravis and the Safety of Vaccines: Data from an Italian Cohort , 2022, Neurology international.
[2] J. Statland,et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial , 2021, The Lancet Neurology.
[3] F. Shi,et al. Incidence, mortality, and economic burden of myasthenia gravis in China: A nationwide population-based study , 2020, The Lancet regional health. Western Pacific.
[4] F. Shi,et al. Immunotherapy choice and maintenance for generalized myasthenia gravis in China , 2020, CNS neuroscience & therapeutics.
[5] M. Lipowska,et al. Determinants of Quality of Life in Myasthenia Gravis Patients , 2020, Frontiers in Neurology.
[6] H. Kaminski,et al. Gender differences in quality of life among patients with myasthenia gravis in China , 2020, Health and Quality of Life Outcomes.
[7] Li Yang,et al. Fatigue, self-efficacy and psychiatric symptoms influence the quality of life in patients with myasthenia gravis in Tianjin, China , 2020, Journal of Clinical Neuroscience.
[8] L. Mao,et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. , 2020, JAMA neurology.
[9] M. Benatar,et al. Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis , 2020, JAMA neurology.
[10] J. Verschuuren,et al. Emerging therapies for autoimmune myasthenia gravis: Towards treatment without corticosteroids , 2019, Neuromuscular Disorders.
[11] L. Prieto-Pinto,et al. Quality of life in refractory generalized myasthenia gravis: A rapid review of the literature. , 2019, Intractable & rare diseases research.
[12] P. van Damme,et al. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis , 2019, Neurology.
[13] G. L’italien,et al. Impact of Refractory Myasthenia Gravis on Health-Related Quality of Life , 2019, Journal of clinical neuromuscular disease.
[14] N. Gilhus,et al. Myasthenia gravis , 2019, Nature Reviews Disease Primers.
[15] M. Benatar,et al. Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis , 2019, Muscle & nerve.
[16] Xiuying Hu,et al. Translation, cross‐cultural adaptation, and validation of the chinese version of the 15‐item myasthenia gravis quality of life questionnaire , 2018, Muscle & nerve.
[17] A. Jeong,et al. Factors associated with quality of life of people with Myasthenia Gravis , 2018, PloS one.
[18] M. Benatar,et al. Rituximab as treatment for anti-MuSK myasthenia gravis , 2017, Neurology.
[19] Hidekazu Suzuki,et al. Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study , 2017, BMJ Open.
[20] K. Milinis. Randomized Trial of Thymectomy in Myasthenia Gravis. , 2016, The New England journal of medicine.
[21] B. C. O. Valério,et al. Brazilian-Portuguese translation, cross-cultural adaptation and validation of the Myasthenia Gravis Composite scale. A multicentric study , 2016, Arquivos de Neuro-Psiquiatria.
[22] M. Benatar,et al. International consensus guidance for management of myasthenia gravis , 2016, Neurology.
[23] A. Taly,et al. MG-QoL-15 scores in treated myasthenia gravis: Experience from a university hospital in India. , 2016, Neurology India.
[24] Min Zhang,et al. Quality of life in 188 patients with myasthenia gravis in China , 2015, The International journal of neuroscience.
[25] J. Verschuuren,et al. An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts , 2015, Health and Quality of Life Outcomes.
[26] P. Mccombe,et al. Clinical features and impact of myasthenia gravis disease in Australian patients , 2015, Journal of Clinical Neuroscience.
[27] John H Wasson,et al. Patient reported outcome measures in practice , 2015, BMJ : British Medical Journal.
[28] J. Sieb. Myasthenia gravis: an update for the clinician , 2014, Clinical and experimental immunology.
[29] Jacqueline Palace,et al. Myasthenia gravis and neuromyelitis optica spectrum disorder , 2012, Neurology.
[30] Antonio Pflüger,et al. Executive Summary. , 2012, Journal of the ICRU.
[31] M. Conaway,et al. The MG Composite , 2010, Neurology.
[32] F. Cantor. Central and Peripheral Fatigue: Exemplified by Multiple Sclerosis and Myasthenia Gravis , 2010, PM & R : the journal of injury, function, and rehabilitation.
[33] M. Conaway,et al. Less is more, or almost as much: A 15‐item quality‐of‐life instrument for myasthenia gravis , 2008, Muscle & nerve.
[34] H. Bard. [Update for the clinician]. , 2005, Journal de radiologie.
[35] Emily Best. A rapid review of the literature , 2005 .
[36] D B Sanders,et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. , 2000, Neurology.
[37] R. Barohn,et al. Myasthenia gravis , 2000, Neurology.